Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yasuo Hamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5737-122X; OpenAlex author ID A5041844936. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis. Last author DOI 10.1007/s10147-025-02713-5↗
  2. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. First author DOI 10.1007/s10637-018-0589-6↗
  3. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemo… First author DOI 10.1007/s00280-017-3263-3↗
  4. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  5. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  6. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Co-author DOI 10.1111/cas.12621↗
  7. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Co-author DOI 10.1111/cas.12059↗
  8. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Co-author PMID 22993328↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takanori Kanai∥ · 3 shared papers, 2017–2025 · strength 0.37
  2. Hiromasa Takaishi · 5 shared papers, 2012–2018 · strength 0.24
  3. Hideyuki Hayashi · 1 shared paper, 2025 · strength 0.22
  4. Eiichiro So · 1 shared paper, 2025 · strength 0.22
  5. Hiroshi Nishihara · 1 shared paper, 2025 · strength 0.22
  6. Akiyoshi Kasuga · 2 shared papers, 2017–2018 · strength 0.14
  7. Shoji Nakamori · 2 shared papers, 2015–2017 · strength 0.08
  8. Shinichi Ohkawa · 2 shared papers, 2015–2017 · strength 0.08
  9. Akihiro Funakoshi · 2 shared papers, 2015–2017 · strength 0.08
  10. Takuji Okusaka · 2 shared papers, 2015–2017 · strength 0.08
  11. Naohiro Okano · 1 shared paper, 2018 · strength 0.07
  12. Koichi Aiura · 2 shared papers, 2013–2015 · strength 0.07
  13. Yuko Kitagawa · 2 shared papers, 2013–2015 · strength 0.07
  14. Toshifumi Hibi∥ · 2 shared papers, 2012–2013 · strength 0.06
  15. Taketo Yamaguchi · 1 shared paper, 2017 · strength 0.05
  16. Takashi Hatori · 1 shared paper, 2017 · strength 0.05
  17. Hirofumi Fujii · 1 shared paper, 2017 · strength 0.05
  18. Tatsuya Ioka · 1 shared paper, 2017 · strength 0.05
  19. Shinichi Egawa · 1 shared paper, 2017 · strength 0.05
  20. Narikazu Boku · 1 shared paper, 2017 · strength 0.05
  21. Ann‐Lii Cheng · 1 shared paper, 2017 · strength 0.05
  22. Junji Furuse · 1 shared paper, 2017 · strength 0.05
  23. Yasuo Ohashi · 1 shared paper, 2017 · strength 0.05
  24. Hideki Ueno · 1 shared paper, 2017 · strength 0.05
  25. Masao Tanaka · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.